KAUFX
Price
$6.12
Change
+$0.01 (+0.16%)
Updated
Sep 20 closing price
RPTIX
Price
$109.40
Change
-$0.77 (-0.70%)
Updated
Sep 20 closing price
Ad is loading...

KAUFX vs RPTIX

Header iconKAUFX vs RPTIX Comparison
Open Charts KAUFX vs RPTIXBanner chart's image
Federated Hermes Kaufmann R
Price$6.12
Change+$0.01 (+0.16%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Mid-Cap Growth I
Price$109.40
Change-$0.77 (-0.70%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
KAUFX vs RPTIX Comparison Chart
Loading...
VS
KAUFX vs. RPTIX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KAUFX is a StrongBuy and RPTIX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RPTIX has more cash in the bank: 31.4B vs. KAUFX (5.12B). RPTIX pays higher dividends than KAUFX: RPTIX (0.18) vs KAUFX (0.00). KAUFX was incepted earlier than RPTIX: KAUFX (39 years) vs RPTIX (9 years). KAUFX is a more actively managed with annual turnover of: 57.00 vs. RPTIX (21.70). KAUFX has a lower initial minimum investment than RPTIX: KAUFX (0) vs RPTIX (500000). KAUFX annual gain was more profitable for investors over the last year : 26.97 vs. RPTIX (14.81). RPTIX return over 5 years is better than : 15.09 vs. KAUFX (-4.52).
KAUFXRPTIXKAUFX / RPTIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence39 years9 years-
Gain YTD16.3509.127179%
Front LoadN/AN/A-
Min. Initial Investment0500000-
Min. Initial Investment IRAN/AN/A-
Net Assets5.12B31.4B16%
Annual Yield % from dividends0.000.18-
Returns for 1 year26.9714.81182%
Returns for 3 years-20.62-13.57152%
Returns for 5 years-4.5215.09-30%
Returns for 10 years-5.85N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLH246.88-0.54
-0.22%
Clean Harbors
TOI0.29N/A
-0.58%
Oncology Institute (The)
CINT6.59-0.04
-0.60%
CI&T
CSTM16.22-0.54
-3.22%
Constellium SE
KTTA4.43-0.37
-7.71%
Pasithea Therapeutics Corp